Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Launching Co-Pay programs for ZTlido and ELYXYB for commercially insured patients
Multi-State Medicaid Pharmaceutical Purchasing Group added ELYXYB to its purchasing pool
爲商業保險患者推出ztLido和ELYXYB的自付計劃
多州醫療補助藥品採購集團將ELYXYB添加到其採購池中
PALO ALTO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced launching of co-pay programs for both ZTlido and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido, and migraine product, ELYXYB. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients.
加利福尼亞州帕洛阿爾託，2024年4月9日（GLOBE NEWSWIRE）——專注於收購、開發和商業化用於治療急慢性疼痛的非阿片類疼痛管理產品的創新創收公司Scilex控股公司（納斯達克股票代碼：SCLX，“Scilex” 或 “公司”）今天宣佈自付啓動ZTLido和ELYXYB的自付計劃其針對商業保險患者的產品組合的費用上限爲每月25美元，某些符合條件的患者支付的費用低至0美元。這適用於該公司的帶狀皰疹後遺神經痛止痛產品ztLido和偏頭痛產品ELYXYB。Scilex已進行了大量投資，以提高患者的可負擔性和獲得其產品的機會，並將繼續在公司向患者提供非阿片類藥物疼痛管理產品的承諾基礎上再接再厲。
Additionally, on April 1, 2024, a multi-state Medicaid pharmaceutical purchasing group added ELYXYB to its purchasing pool to make it eligible for thirteen States' Medicaid programs.
此外，2024年4月1日，一個多州醫療補助藥品採購集團將ELYXYB添加到其購買池中，使其有資格參加13個州的醫療補助計劃。
Scilex believes that high deductibles and co-pay programs should not prevent patients from receiving the medications they need. Scilex co-pay programs are designed to help patients reduce their co-pay and out-of-pocket costs for their medications. Our program partners with various assistance programs to help make patient medications more affordable.
Scilex認爲，高免賠額和自付額計劃不應阻止患者獲得所需的藥物。Scilex自付計劃旨在幫助患者減少藥物的自付費用和自付費用。我們的計劃與各種援助計劃合作，以幫助患者更實惠地使用藥物。